Southern Research Institute

Merck Sharp + Dohme Corp.

Robert C Reynolds

John A Secrist, Iii

Joseph A Maddry

F George Njoroge

Subramaniam Ananthan

Cecil D Kwong

Hollis S Kezar, Iii

Neng-Yang Shih

John J Piwinski

Feng Geng

Abhijit Roychowdhury

Frank W Bennett

Ashok Arasappan

Jeremy Clark

Anita T Fowler

Srikanth Venkatraman

Vinay M Girijavallabhan

Francisco Velazquez

Vishal Verma

Yuhua Huang

Gary A Piazza

Joseph A Kozlowski

Peter Anthony Crooks

John A Montgomery

Ling Tong

Malcolm Maccoss

Bandarpalle B Shankar

Seong Heon Kim

Bini Mathew

E Lucile White

William J Suling

Regina Huelgas

Robert W Buckheit, Jr

Robert N Comber

John A Secrist

Hollis S Kezar

John A Iii Secrist

Hollis S Iii Kezar

George F Njoroge

Iii Hollis S Kezar

Iii John A Secrist

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, Rand n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.

Derivatives of sulindac, use thereof and preparation thereof

The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, R, R, R, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and pro-drugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, Rand n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, R, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

Derivatives of sulindac are provided along with pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.

The invention relates to inhibitors of FtsZ polymerization and uses thereof.

Inhibitors of FtsZ and uses thereof

A series of 5,5-disubstituted Hydantoin derivatives synthesized by alkylating 5,5-bis(thiomethyl)-2,4-imidazolidinedione with halomethyl aromatic or halomethyl heteroaromatic precursors or by using the Buchener-Berg procedure on the required ketone. This series of 5,5-disubstituted Hydantoin derivatives are biologically active in their ability to inhibit HIV-induced death and virus production in mammalian (human) cells.

5,5-Disubstituted hydantoins

The present invention provides for the preparation and use of ribo- and deoxyribo-nucleosides and polynucleotide analogs. The polynucleotide analogs are made of polynucleosides which contain sulfonate and sulfonamide linkages.

Polynucleotide analogs containing sulfonate and sulfonamide

Growing community of inventors

Birmingham, AL, United States of America

Robert C Reynolds